Dr. Sparano on Application of Liquid Biopsies in Breast Cancer

Video

In Partnership With:

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses the application of liquid biopsies in breast cancer.

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses the application of liquid biopsies in breast cancer.

He says that while a liquid biopsy has some advantages over the standard tissue biopsy, there are some challenges that remain before it becomes part of routine clinical practice. The biggest challenge is that liquid biopsies have not yet been clinically proven to result in beneficial treatment for patients. While they are useful in detecting the mutational profile of a tumor, there is still work to be done in improving their clinical utility.

There might be some exceptions to that, says Sparano. Liquid biopsies can be useful in detecting ESR1 mutations, which are frequently found in the blood and usually come as a result of resistance to aromatase inhibition for patients with estrogen receptor-positive disease. Liquid biopsies are also effective in locating circulating tumor DNA.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine